autism-vaccine link?

Varicella vaccine:

The all the cost-effectiveness studies I have seen to date have been performed assuming a single dose would be required. It is now know at least two are required, and the possibility of having to vaccinate a load more people against HZ for the next 20-30 years is looking more likely. IIRC, the HZ vaccine is an even more expensive than the Varicella vaccine.

It seems bizarre to me (as an engineer who has worked on high-volume cost-sensitive projects worth hundreds of millions, where adding less than 10% to the estimated manufacturing cost is questioned), that a 200-400% increase is being ignored in the US, especially when one of the primary reasons given for the introduction of the vaccine was that is was cost-effective.
My view on this is that the objective is to eradicate the disease and then our children's children won't have to worry about either the vaccine or chicken pox/shingles.
 
My view on this is that the objective is to eradicate the disease and then our children's children won't have to worry about either the vaccine or chicken pox/shingles.

I think that's a worthy goal. Given the infectiousness of varicella, I think it's only realistic if the majority of the other 6 billion people on the earth buy into it.
 
I think that's a worthy goal. Given the infectiousness of varicella, I think it's only realistic if the majority of the other 6 billion people on the earth buy into it.
Good point and there are other diseases higher on the list.
 
I didn't mean anything different between those two examples (other than in one case the 'reality' would be the accuracy of the diagnosis and in the other it would be the accuracy of the risk assessment).
Okay. I interpreted it as saying two very different things.
That's not quite what I meant. How you ask or present each of those questions can lead to a different answer (like whether you present it as a gain or a loss). For example, if you need $80,000 for your child's college education, pointing out that banking your child's blood will allow you to save $60,000 toward the cost or banking your child's blood means you lose $20,000 of your college fund will get you two different answers. Which one is correct?
Neither. I’m quite aware that presentation of material can make a huge difference. But is there any legitimate reason for you, as a doctor, to put any sort of spin on the information? What's wrong with simply saying “banking your child's blood may be a lifesaving measure if he/she later comes down with leukemia or another disease that might be cured with their own stem cells. The risk of that is XX%. The cost is $20,000.”
Why ‘spin’ the information you give them at all. What’s wrong with a neutral presentation?

Now, Linda, I like to go back to a topic that was discussed previously. I’m going to quote some of our previous posts to try and make it coherent.
And that beautifully illustrates the issue. As I have mentioned previously, my graduate work was in public health including economic analysis. My residency and fellowship research was on vaccine policy. And I have years of clinical experience as well as serving in an advisory role when it comes to policy.
As someone who is involved in setting policy, it’s nice to have your ear. I would really like to see some reforms on vaccine policy in the US. While I’m not going to be making many more decisions, my children will someday. It would be nice if they could simply rely on the official recommendations.
I'm not saying this as any sort of appeal to authority. I'm saying this in order to make it explicit that this clearly is not about 'who' knows 'what'. The perception of credibility has almost nothing to do with knowledge.
While this is a valid point, it’s not entirely true. I think that people who are recognized as experts in the field do receive some credibility on the matter. Their opinions are not dismissed as easily as those who do not have that expertise.
If we keep on pretending that this issue has anything to do with knowledge about vaccines or knowledge about who should or should not be considered credible, I think we are missing the boat.
I’d like to know what you do think the important issue is if it isn’t either of those two things.

I think the issue is that knowledge/information isn't used to determine who should or should not be considered credible
When you say this, isn’t that a combination of those two things?

That's what I suspected. You used yourself as the 'gold standard' by which to assess the performance of the committee (without confirming the validity of that standard) and made assumptions which justified a decision you had already made. And this is pretty consistent with our understanding of how people make and justify their decisions.
How exactly do you think I should evaluate the quality of their decisions rather than researching things for myself and seeing how often I agree with them? If I'm not going to use myself as the 'gold standard', what am I supposed to use to evaluate the quality of their decisions? You? Some other stranger on the internet?
You never actually answered this question. I would appreciate it hearing how you think others should evaluate the quality of policy decisions made by experts? This, btw, is a question that applies to far more things than vaccine policy. Our society has some very complicated mechanisms for setting policy. How can an individual who is not an expert in the area evaluate when a policy setting committee is making good choices and when they are not?
What's wrong with letting people who know what they're doing do the job?
Now we're back to the credibility issue. The people who know what they're doing do not necessarily have the best interests of me and my family in mind when they make their decisions. In fact, as I've read through their justifications for their decisions, it's clear they don't.
Ivan has given a pretty good summation of what he has done for research. You think it is insufficient. I have explained why I don’t feel I can trust the ACIP recommendations. You haven’t really commented much on that.

So what exactly do you think people should do in terms of making these decisions for themselves. Do you think it’s best for everyone to just trust unquestioningly what the medical authorities tell them they should do? If not, what do you think is the best approach for people to take when making such decisions? If you think people should inform themselves of the benefits and risks before making a decision, one consequence of that approach is that some people will research the risks and benefits and come to different conclusions than you.
 
Last edited:
For such a successful profession as modern medicine, it amazes me when people draw a conclusion such as this.
No more amazing that the conclusions you have drawn from my post. :)
Might it not be just as reasonable that people such as Linda, Deetee and myself take pride in doing a good job? That we take pride in staying abreast of the latest and best information on which to make our practice decisions?
Yes, that's quite reasonable, but it doesn't mean you are not biased.
Medicine (and nursing) are difficult professions. When a mistake is made or a failure occurs and one finds out one wasn't aware of some new discovery or research, people can suffer, people can die. How do you think that might affect someone's practice? I'm not in the business of selling anything. I am in the business of providing good medical and nursing care.
Okay. This still doesn't imply that you aren't biased.
Most health care providers (and there are exceptions) are interested in providing the best care, whatever that may be. That means evidence based medicine. If it were more prevalent that providers merely stuck with some dogma they were sold on at some point in school or in their practices, we'd still be draining blood from wrists as the preferred method of treating disease.
Okay. I agree. It still doesn't mean you aren't biased.

I did not say, nor did I intend to imply any of the things you have inferred.

There's a reason that committees are formed to set policy and a reason they should include people from a variety of different backgrounds and expertise, holding a variety of different opinions. We can't eliminate bias, but we can try to balance it. That the ACIP committee is not well balanced is IMO a serious problem. I double it is unique to their committee. I suspect, particularly under this administration, that it is a ubiquitious problem across our government. The management of the Iraq war screams groupthink to me. The administration simply didn't listen to anyone who told them the expected outcome was not going to be what they wanted.
 
Last edited:
Varicella vaccine:

The all the cost-effectiveness studies I have seen to date have been performed assuming a single dose would be required. It is now know at least two are required, and the possibility of having to vaccinate a load more people against HZ for the next 20-30 years is looking more likely. IIRC, the HZ vaccine is an even more expensive than the Varicella vaccine.

It seems bizarre to me (as an engineer who has worked on high-volume cost-sensitive projects worth hundreds of millions, where adding less than 10% to the estimated manufacturing cost is questioned), that a 200-400% increase is being ignored in the US, especially when one of the primary reasons given for the introduction of the vaccine was that is was cost-effective.
Since this is a continuation of a previous thread discussion, permit me to remind you of what you failed to include in your cost/benefit assessment then and now. You neglected to include the cost of lost work time, the cost of hospitalizations, the costs of doctor's visits, the cost of additional morbidity and mortality that occurs from being in any hospital that is not recorded as a direct cost of varicella disease, the outbreaks of invasive group A strep (aka flesh eating infections) in children with acute chicken pox, the cost of long term health care for those suffering permanent lung damage from varicella and the tragedy of the loss of a loved one, especially a child or young adult who may be the parent of a young child.

As I reviewed several abstracts where the authors concluded it best regarding cost/benefit to vaccinate teens and older for varicella, I noticed two recurring themes.

One, they underestimate the actual cost of varicella morbidity and mortality due to what was included in the impact of varicella.

And two, more importantly, the cost benefit impact was to the third party payer's budget whether that be national health insurance or a private insurance company. If a parent loses work time with an ill child, that isn't a concern of the insurer. If a parent loses their child, that doesn't count as a cost to the insurer.

NACI [Canadian ACIP equivalent] UPDATE TO STATEMENT ON VARICELLA VACCINE
Varicella is often considered to be a fairly benign disease among otherwise healthy children < 12 years of age. However, not only does this group account for approximately 90% of all varicella cases, but also for 80% to 85% of varicella-associated physician visits, 85% to 90% of hospitalizations, nearly 50% of fatal cases and the majority of annual costs, most of which are related to productivity losses by caregivers.

Complications include secondary bacterial skin and soft tissue infections, otitis media, bacteremia, osteomyelitis, septic arthritis, endocarditis, necrotizing fasciitis, toxic shock-like syndrome, mild hepatitis and thrombocytopenia. Studies in Canada and the United States (U.S.) have estimated that varicella increases the risk of severe invasive Group A beta hemolytic streptococcus (GABHS) infection among previously healthy children, by 40- to 60-fold(4,11). Rare neurologic complications include cerebellar ataxia and encephalitis. Complications are more likely to occur when chickenpox is acquired in adolescence or adulthood, with higher rates of pneumonia, encephalitis and death. Case fatality rates among adults are 10 to 30 times higher than in children. In the U.S., adults account for only 5% of cases, but constitute 55% of an approximate 100 chickenpox deaths each year. In Canada, 70% of the 53 reported chickenpox deaths from 1987 to 1996 were among those > 15 years of age.

The medical and societal costs of varicella in Canada were estimated, from a multicentre study, as a total yearly cost of $122.4 million dollars, or $353.00 per individual case(5,6). Eighty-one percent of the costs went towards personal expenses and productivity costs, 9% towards the cost of ambulatory medical care and 10% towards hospital-based medical care.
Here the costs measured included a broad range of consequences including the costs of all the uncomplicated childhood cases. Those costs are completely left out of any number of analyses which only looked at the cost of severe disease as if routine cases had no financial impact.

Compare that to this discussion, The cost-effectiveness of varicella vaccination in Canada.
A deterministic realistic age-structured model was used to predict the impact of vaccination on the incidence of varicella and zoster. Unit costs, estimated from literature, were applied to the predicted health outcomes. Various vaccination programs were investigated and a sensitivity analysis was performed. Assuming no impact of vaccination on zoster, varicella vaccination is estimated to cost 45,000 dollars, 51,000 dollars and 18,000 dollars per life-year gained from the health payer's perspective for infant, infant with catch-up campaign, and preteen programs, respectively. From the societal perspective, mass infant varicella vaccination was estimated to be highly cost saving in Canada. Importantly, infant varicella vaccination could result in a short- to medium-term increase of zoster incidence and thus cause vaccination to be highly cost-ineffective (118,000 dollars per life-year gained) under the health payer's perspective. From a health payer's perspective the preteen vaccination is the only strategy that is deemed cost-effective. The cost-effectiveness of infant vaccination rests heavily on the unknown relationship between varicella and zoster.



Decline in Mortality Due to Varicella after Implementation of Varicella Vaccination in the United States
Results The rate of death due to varicella fluctuated from 1990 through 1998 and then declined sharply. For the interval from 1990 through 1994, the average number of varicella-related deaths was 145 per year (varicella was listed as the underlying cause in 105 deaths and as a contributing cause in 40); it then declined to 66 per year during 1999 through 2001. For deaths for which varicella was listed as the underlying cause, age-adjusted mortality rates dropped by 66 percent, from an average of 0.41 death per 1 million population during 1990 through 1994 to 0.14 during 1999 through 2001 (P<0.001). This decline was observed in all age groups under 50 years, with the greatest reduction (92 percent) among children 1 to 4 years of age. In addition, by the period from 1999 through 2001, the average rates of mortality due to varicella among all racial and ethnic groups were below 0.15 per 1 million population, as compared with rates ranging from 0.37 per 1 million for whites to 0.66 per 1 million for other races in the period from 1990 through 1994.

Conclusions The program of universal childhood vaccination against varicella in the United States has resulted in a sharp decline in the rate of death due to varicella....

...Discussion

An average of 145 varicella-related deaths per year occurred in the United States from 1990 through 1994, a higher number than was previously recognized, owing to the fact that reports had been based solely on deaths for which varicella was listed as the underlying cause. Since the implementation of the varicella vaccination program, varicella-related deaths have declined dramatically to the lowest level ever reported; rates of mortality due to varicella in the United States are now considerably lower than the reported rates in countries that do not have a universal vaccination program.12,13,14,15,16,17 Varicella-related deaths have declined among children and among adults 20 to 49 years of age, and mortality rates are similar for all racial and ethnic groups and for persons born inside the United States and those born in other countries. However, most deaths related to varicella continue to occur among persons who do not have high-risk conditions and who are eligible for vaccination.
Again, costs are often underestimated because the calculations are limited to direct costs of varicella only. The cost of a number of complications did not count.

Additional studies people might want to look at:

Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States.

Impact of varicella vaccination on health care utilization.



Additionally I noticed in these cost benefit analyses there was the assumption that zoster would increase. Few attempts were made to address decreasing the increase in zoster cases by boosters and calculate the entire cost. So you have to look at whose cost is being looked at when evaluating varicella vaccine, and you need to determine just what is being included in the calculations.

It isn't clear just what an increase in zoster cases in people with healthy immune systems will mean. It could be that those are not the persons who would suffer complications from zoster anyway. After all, you are talking about zoster cases that would have been prevented by natural exposure boosting. One might hypothesize that those would be more likely to be mild uncomplicated cases and zoster occurrences not prevented by natural exposure boosting were more likely to be complicated cases. In any case, I think it is too easy to overlook these multiple variables and erroneously come up with data to support the vaccine not being cost effective.

Regarding the increase in zoster following introduction of vaccine, the Australian public health recommendation had this in their discussion:

The Australian Immunisation Handbook - 3.27 VARICELLA-ZOSTER
Two epidemiological studies from the United Kingdom suggest that exposure to varicella may help prevent herpes zoster, presumably by boosting immunity. 11,12 A study using mathematical modelling and a number of assumptions has predicted that, following the introduction of varicella-zoster vaccination, there could be a short to medium term increase in the incidence of herpes zoster with a shift in the age of cases into younger age groups (because naturally infected persons would have less opportunity to be exposed to varicella). 11,13 However, as the vaccine strain of varicella virus causes herpes zoster significantly less frequently,8 not only varicella but also herpes zoster could ultimately be eliminated. It must also be emphasised that there is no direct proof that herpes zoster epidemiology will be altered by the introduction of varicella-zoster vaccination. Indeed, current surveillance in USA shows no change in herpes zoster incidence after 5 years of routine vaccination. In Australia, South Australia began passive surveillance of varicella and herpes zoster from January, 2002. Other surveillance mechanisms are in place nationally (eg. hospitalisations) to track the varicella and herpes zoster disease burden following the introduction of vaccination programs.
Other studies did not corroborate the failure to see increased zoster but most of the discussions relied on long term modeling projected increases based on short term data sets.



BTW, here's another lesson in how to misunderstand a medical researhc abstract when you don't have a thorough understanding of a disease.
Epidemiology of varicella-zoster virus in England and Wales
Abstract
Many countries are studying currently the possibility of mass vaccination against varicella. The objective of this study was to provide a complete picture of the pre-vaccine epidemiology of the Varicella-Zoster Virus in England and Wales to aid in the design of immunisation programs. Population-based data including general practitioner sentinel surveillance, hospitalisation data, and death certificates from England and Wales were analysed. The average incidence rates for varicella and zoster between 1991 and 2000 were 1,291 and 373 per 100,000 years, respectively. Overall hospitalisation rates were equal for varicella and zoster (4.5 vs. 4.4 hospitalisation per 100,000 population) with 5 and 8%, respectively, having underlying immunosuppressive conditions. The age-specific proportion of cases hospitalised and length of stay were similar between the two diseases. However, the overall burden of disease is considerably higher for zoster. The number of inpatient days and case-fatality due to zoster are roughly 4 to 6 times greater than for varicella (11 vs. 3 days and 25 vs. 4 deaths per 100,000 case). These results provide base-line estimates should mass varicella vaccination be introduced in England and Wales.
The baseline referred to here is intended to be compared to changes over time with implementation of vaccine programs. The conclusion for this abstract is in the italicized text.

There is not a claim here that primary varicella is not as bad as zoster. If you don't understand the disease, the population affected, the expected course of disease, then you are going to grossly misunderstand what the bolded text means. I can't overemphasize this enough. Nothing here says that without natural boosting, zoster is going to hospitalize or kill more people. Nothing here says that without natural boosting zoster will be more dangerous to people with healthy immune systems. This says nothing of the kind. You cannot assess the increased risk of zoster from decreasing primary chicken pox from the bolded data. You have no denominators. And all those people with zoster also had chicken pox initially. The disease process differs between the two presentations of the infection. The average age and additional disease conditions vary between the two groups.

As a medical practitioner, I don't draw the conclusion from this that having natural virus around boosting people against zoster is better than vaccinating people. I can see why the statement is being misunderstood.

I ask the other physicians and practitioners here to give their take on that bolded text and how it is being misunderstood by Ivor. I'm at a loss for words to explain it in 25 words or less.
 
Last edited:
It's cheaper to let people suffer and die, cuz then the jobs can be taken by someones who are not injured or dead because of diseases, those other wimps can just suffer and die and we won't have to bother with the cost of making vaccines. Suffering and dying is better too, cuz then you haven't messed with the natural immunity of the human body.

:p:p:p
 
Seasonal flu vaccine:

My main puzzlement is over how the ACIP in the US can conclude from the evidence that vaccinating 73%-100% of the US population is justified, whereas in the UK, the JCVI looking at practically the same evidence recommends only specific at-risk groups, health care workers and people over the age of 65. The UK policy is similar to the ACIP 1983 one I linked to earlier.

I was particularly interested in the article by Tom Jefferson because he highlights the burden of Influenza-A/B as a proportion of Influenza + Influenza-Like-Illness may typically only be ~15% (again, IIRC). So that raises the question of why invest so much in the flu vaccine when 85% of people who have flu-like symptoms are not going to benefit?
Jefferson merely complained about using ILIs as a measure of influenza. As I said, Jefferson complained there were no direct measurements of how much ILI was actual influenza. He is wrong. We have that data at least in the US, even if every study does not use the sentinel epidemiological data.

Again, just as with varicella, you are not looking at the full burden of disease. And in the case of influenza, you are not considering the current approach of eliminating the reservoir in children in order to address the burden in the elderly.

I'm concerned that so many people underestimate the severity of influenza. We don't know until flu season is in progress just how many otherwise healthy individuals and particularly children are going to die from flu. And if you wait to see, then it is too late.

And as I said to you many times, I don't give a ◊◊◊◊ about your tax burden, I'll pay for my kid's flu shot any day regardless of how much risk I'm reducing for my buck. Flu shots are relatively cheap compared to the cost of preventing many other pediatric risks.
 
No more amazing that the conclusions you have drawn from my post. :)
Perhaps you don't recognize the implications of your conclusion, Beth.

You imply that our bias is with the vaccination rather than with the evidence. You imply actually, made a direct accusation, that we follow the ACIP blindly rather than assess a source for the supportability of their conclusions.


Yes, that's quite reasonable, but it doesn't mean you are not biased.
Okay. This still doesn't imply that you aren't biased.
Okay. I agree. It still doesn't mean you aren't biased.

I did not say, nor did I intend to imply any of the things you have inferred.

There's a reason that committees are formed to set policy and a reason they should include people from a variety of different backgrounds and expertise, holding a variety of different opinions. We can't eliminate bias, but we can try to balance it. That the ACIP committee is not well balanced is IMO a serious problem. I double it is unique to their committee. I suspect, particularly under this administration, that it is a ubiquitious problem across our government. The management of the Iraq war screams groupthink to me. The administration simply didn't listen to anyone who told them the expected outcome was not going to be what they wanted.
And, as Linda has already pointed out, yet you ignore, the ACIP is not alone in it's conclusions. The WHO, Australia and Canada to name a few have made corroborating conclusions from their analysis of the data. And as I have pointed out and you continue to ignore, the ACIP does its business in full view.

Can you cite any legitimate medical professionals or professional group that has major criticisms of the bias you assume is in the ACIP recommendations because you read some of the members have some ties to pharmaceutical companies?
 
Aww forget about it, an ounce of prevention ain't worth nada to some people. They'd rather argue semantics from assumptions and made up theories about big pharma keeping us all sick to make a profit.

-peanut gallery

I must say I do really appreciate Linda's and Skeptigirl's posts though. And they are a welcome read after most of the other junk other people post without really knowing what they are talking about.
 
Last edited:
A brief fly-by post..... (very busy these days)

Remember there are a number of ways of assessing any intervention. There is the cost-benefit or cost-effectiveness measure, which is somewhat different to the risk-benefit equation.

In medicine, to help compare between interventions, health economists will use a guide such as the quality adjusted life year (QALY) or the disability adjusted life year (DALY), as an indication of the value attached to the outcome of a medical intervention. These can be used to prioritise the use of scarce resources, and cost-benefit analysis is used to do this.

Ivor tends to look at things from this more economic perspective, which is fine, and his arguments are quite valid when one considers the possible "benefits" of using a vaccine against varicella, flu or HPV.

However, there are many other things to consider in medicine. When there is potential for direct harm to individuals if a particular intervention is not used (be it a vaccine, or expensive chemotherapy) the issue becomes more emotive and complex. You see, medical people (and lay people also) often see things primarily in terms of the risk-benefit equation - and if an intervention is likely to do more good than harm, it becomes almost impossible to resist its use. So skeptigirl wants to use varicella vaccine, quite appropriately, because her primary focus is the welfare of children, and not the economic costs of the vaccination strategy.

These two viewpoints are not inconsistent or incompatible. I am sure skeptigirl would agree that if cost were the defining criterion, it would be better to vaccinate for measles than varicella. Ivor, OTOH, should appreciate that in medicine, certain things get done because they are the right and proper thing to do, and not merely because a health economist has determined it is allowable because it has passed some cost-benefit analysis threshold. As an example, we consider it right and proper to offer neonatal intensive care facilities to premature babies, when logic and economics dictates we should put our money into a diferent area of medical care. There are countless examples outside of medicine as well - we accept that hundreds of police (using hundreds of thousands of pounds of taxpayers money) should spend months trying to find abducted children, not because it is cost effective, but because morally it is the right and proper thing to do. If we were to stop doing these things, and only do the things which are cost-effective, our society would be a wholly unpleasant one in which to live.
 
Last edited:
Perhaps you don't recognize the implications of your conclusion, Beth.

You imply that our bias is with the vaccination rather than with the evidence. You imply actually, made a direct accusation, that we follow the ACIP blindly rather than assess a source for the supportability of their conclusions.
No, that is not a direct accusation. It isn't even implied. You infer more than is meant. I don't think you or Linda follow their directives blindly. However, I do think a lot of pediatricians do.
And, as Linda has already pointed out, yet you ignore, the ACIP is not alone in it's conclusions. The WHO, Australia and Canada to name a few have made corroborating conclusions from their analysis of the data. And as I have pointed out and you continue to ignore, the ACIP does its business in full view.
Actually, I pointed out in a previous post how grateful I am to live in a country that puts all this information out in full view. I also agree that the additional countries are a good way to validate their decisions. On the other hand, as Ivor has pointed out, they do not agree entirely and it is in the areas where they do not agree that he and I have concerns. We are NOT disputing the value of vaccines like polio or MMR.
Can you cite any legitimate medical professionals or professional group that has major criticisms of the bias you assume is in the ACIP recommendations because you read some of the members have some ties to pharmaceutical companies?
Not today. I have in the past. That was why I looked into it in the first place. Ended up writing my congressman to complain - fat lot of good that did! Anyway, I suspect that if I were to search and find some professions that do, you would simply find some reason to dismiss them as not being legitmate.
 
Last edited:
Skeptigirl,

There is no point discussing this with you. No matter how much reading or research I do it will never be enough, simply because I'm not a medical professional. As far as you (and EotE) are concerned, my opinions, those of the experts and the evidence I quote, have no validity unless they coincide with your own.

Deetee,

Thank you for another interesting (and non-patronising;)) post. I’m aware of the various types of equity in health care, and can appreciate medical professionals (and myself in their shoes) are, in general, going to favour intervention.

I'll now bow out of the discussion and try to avoid bringing up my uninformed opinions on this and virtually every other subject which are posted on the forum.:)
 
Last edited:
Ivor, it's just sad that you let us all know that it is not worth helping someone to live a disease-free life unless it's dirt cheap and "big pharma" loses money on it. That is pretty much how it is anyways, but it's still not good enough for you.

I don't know what it takes for you to care about human life, but I guess, as you said, nothing will ever be enough.

I only hope you come face to face with it someday, that may work. You're in a nice place pretty much free of disease, and you have no clue if you want to say not everyone deserves what you have unless it's "cost effective" in your opinion.
 
http://www.unicef.org/media/media_9772.html

Measles alone kills nearly 800,000 children every year. There is no excuse for this, when we have a vaccine available for eleven cents.
-2002


http://www.unicef.org/media/media_36233.html - 2007
Measles immunization carries the highest health return for the money spent saving more lives per unit cost. The vaccine, which has been available for more than 40 years,costs about US $0.30 per dose ($0.15 for the vaccine itself and $0.15 for the safe injection equipment) if procured through UNICEF.


According to WHO data, global measles deaths fell from an estimated 873,000 deaths in 1999 to 345,000 in 2005. In Africa, the progress was even greater, with measles deaths falling by 75 per cent, from an estimated 506,000 to 126,000.

And I want vaccines for my children, and am willing to pay for them, and do appreciate that I don't have to pay for most of them. I find that non-suffering is worth the price. No matter what misinformed people say about the vaccines, they do not cause autism. Autism rates at 1/150 are STILL lower than the schizophrenic rates of 1/100.

Putting a price on children's health and the health of the golbal community by examining "cost effectiveness" with untrained eyes to fight this medical miracle is not ethical.

So wander off and whine that the skeptics don't listen to your opinions. I don't care. I care more that vaccines are avaible for my children, and to whomever else that wants them. I'm just glad the evidence points to more value to a human life than your opinion on the subject.
 
Last edited:
Ivor, it's just sad that you let us all know that it is not worth helping someone to live a disease-free life unless it's dirt cheap and "big pharma" loses money on it. That is pretty much how it is anyways, but it's still not good enough for you.

I don't know what it takes for you to care about human life, but I guess, as you said, nothing will ever be enough.

I only hope you come face to face with it someday, that may work. You're in a nice place pretty much free of disease, and you have no clue if you want to say not everyone deserves what you have unless it's "cost effective" in your opinion.

That's a lovely sentiment. How do you know I haven't already?
 
Skeptigirl,

There is no point discussing this with you. No matter how much reading or research I do it will never be enough, simply because I'm not a medical professional. As far as you (and EotE) are concerned, my opinions, those of the experts and the evidence I quote, have no validity unless they coincide with your own.
Nice dodge of the issues I brought up, Ivor. If you can't address them, pretend you have and pretend your arguments were ignored.
 
....Remember there are a number of ways of assessing any intervention. There is the cost-benefit or cost-effectiveness measure, which is somewhat different to the risk-benefit equation.

In medicine, to help compare between interventions, health economists will use a guide such as the quality adjusted life year (QALY) or the disability adjusted life year (DALY), as an indication of the value attached to the outcome of a medical intervention. These can be used to prioritise the use of scarce resources, and cost-benefit analysis is used to do this.

Ivor tends to look at things from this more economic perspective, which is fine, and his arguments are quite valid when one considers the possible "benefits" of using a vaccine against varicella, flu or HPV.

However, there are many other things to consider in medicine. When there is potential for direct harm to individuals if a particular intervention is not used (be it a vaccine, or expensive chemotherapy) the issue becomes more emotive and complex. You see, medical people (and lay people also) often see things primarily in terms of the risk-benefit equation - and if an intervention is likely to do more good than harm, it becomes almost impossible to resist its use. So skeptigirl wants to use varicella vaccine, quite appropriately, because her primary focus is the welfare of children, and not the economic costs of the vaccination strategy.

These two viewpoints are not inconsistent or incompatible. I am sure skeptigirl would agree that if cost were the defining criterion, it would be better to vaccinate for measles than varicella. Ivor, OTOH, should appreciate that in medicine, certain things get done because they are the right and proper thing to do, and not merely because a health economist has determined it is allowable because it has passed some cost-benefit analysis threshold. As an example, we consider it right and proper to offer neonatal intensive care facilities to premature babies, when logic and economics dictates we should put our money into a diferent area of medical care. There are countless examples outside of medicine as well - we accept that hundreds of police (using hundreds of thousands of pounds of taxpayers money) should spend months trying to find abducted children, not because it is cost effective, but because morally it is the right and proper thing to do. If we were to stop doing these things, and only do the things which are cost-effective, our society would be a wholly unpleasant one in which to live.
I agree with you in principle here but would point out a couple things.

One, measles vaccine and varicella vaccine are not an either or proposition so the fact one has greater benefit than the other isn't relevant. However, on that note, I did say that if one were to look at all health care interventions in total and start trimming the least cost effective (in terms of lives saved per dollar spent or some other measure) then if varicella vaccine was the least bang for the buck, Ivor's argument would have more credibility.

Two, even just using financial measures for evaluating the cost benefit of varicella vaccine, the sources Ivor cited were not inclusive of all the actual costs of morbidity. The source I used as an example only considered the cost to a single payer. Left out were costs of lost productivity due to caregivers staying home with ill infectious children. That is a financial cost the ACIP included in their cost benefit analysis because it is a cost to society. An insurance company (be it NHI or private) wouldn't be including costs that do not affect their bottom line in their analyses.

Three, again measuring costs can be deceptive if secondary and tertiary costs of related morbidity and mortality are not considered. The cost and deaths attributed to invasive group A strep secondary to chicken pox, for example, may or may not be included depending on the specific cost benefit analysis. And for example, should that child end up with limb amputation, the cost of long term care may not be considered in the analysis.

Regarding the non-financial costs of varicella mortality, Ivor has in the past ignored these costs outright.
 
No, that is not a direct accusation. It isn't even implied. You infer more than is meant. I don't think you or Linda follow their directives blindly. However, I do think a lot of pediatricians do.
But Linda and I find the ACIP recommendations are evidence based. So if we are not following the ACIP blindly, then the fact some pediatricians are doesn't imply the recommendations are faulty.
.... Anyway, I suspect that if I were to search and find some professions that do, you would simply find some reason to dismiss them as not being legitmate.
So you, like Ivor, make the claim I am simply discounting your conclusions. I propose that I have not been persuaded by your arguments and supporting evidence. To claim I have not given your arguments consideration because I didn't find them convincing is simply not correct. I am not asking you to repost the connections the ACIP members had with the pharmaceutical companies. I never disputed the relationships. I disputed the significance you claimed. Connections or not, the ACIP decision making process is transparent. As such, if the industry influenced the recommendation, then the evidence would reveal that.

I asked you for some corroboration that other professionals or scientists or anyone with sufficient education on the topic agreed that they also detected bias in the ACIP recommendations. It is one thing to claim there could be bias, but another to show there is bias. You have not shown that there is any actual bias. You have only shown that some individual members of the ACIP have also been employed by pharmaceutical companies from time to time.
 
Last edited:
As far as cost benefit goes in evaluating health care interventions, there is also the ease or difficulty implementing the intervention to consider. Vaccinations are easy interventions to implement.

I wonder if you calculated the cost of one or more smoke alarms in every building including maintenance and battery costs if you would be ahead or behind in dollars saved from the costs saved in the fires the alarms affected the outcome of? At first glance it might seem like the alarms would save a lot of money for burn care, funerals and in saved structures. But there are a lot of buildings you'd be putting a smoke alarm in. That cost could add up.

If it the actual cost benefit didn't warrant use of smoke alarms, would anyone really consider quitting using them? Just a thought.
 

ISF - Join now!

Every member here is approved by hand. No bots, no spam, just people who care about evidence and honest debate.

Membership is free!

Create your free account

Back
Top Bottom